CRBX Stock Overview
A biotechnology company develops health testing and microbiome modulators to address a range of chronic and metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Carbiotix AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 9.62 |
| 52 Week High | SEK 139.50 |
| 52 Week Low | SEK 3.58 |
| Beta | 0.82 |
| 11 Month Change | -33.75% |
| 3 Month Change | 43.58% |
| 1 Year Change | -92.15% |
| 33 Year Change | -99.31% |
| 5 Year Change | -98.34% |
| Change since IPO | -98.15% |
Recent News & Updates
Shareholder Returns
| CRBX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.3% | -2.2% | 0.1% |
| 1Y | -92.1% | -6.0% | 11.8% |
Return vs Industry: CRBX underperformed the Swedish Medical Equipment industry which returned -6% over the past year.
Return vs Market: CRBX underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| CRBX volatility | |
|---|---|
| CRBX Average Weekly Movement | 20.0% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: CRBX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CRBX's weekly volatility has decreased from 28% to 20% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Erik Deaner | carbiotix.com |
Carbiotix AB (publ), a biotechnology company develops health testing and microbiome modulators to address a range of chronic and metabolic diseases. Its portfolio includes prebiotic ingredients and diagnostic testing services. The company develops CarbiAXOS, a second-generation prebiotic soluble fiber based on virgin and upcycled natural substrates containing arabinoxylo-oligosaccharides that is customized to meet customer needs to the production of short chain fatty acids or any other effect; and LinkGut, a health test.
Carbiotix AB (publ) Fundamentals Summary
| CRBX fundamental statistics | |
|---|---|
| Market cap | SEK 36.17m |
| Earnings (TTM) | -SEK 16.81m |
| Revenue (TTM) | SEK 3.25m |
11.1x
P/S Ratio-2.2x
P/E RatioIs CRBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBX income statement (TTM) | |
|---|---|
| Revenue | SEK 3.25m |
| Cost of Revenue | SEK 1.40m |
| Gross Profit | SEK 1.85m |
| Other Expenses | SEK 18.66m |
| Earnings | -SEK 16.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.47 |
| Gross Margin | 57.00% |
| Net Profit Margin | -517.25% |
| Debt/Equity Ratio | 0% |
How did CRBX perform over the long term?
See historical performance and comparison